Loading...
Market
Will Stoke Therapeutics enter Phase 3 trials for Dravet syndrome treatment by end of 2025?
3
Sage Therapeutics•Sage•Biogen•Chris Viehbacher•Stoke Therapeutics•Phase•JPMorgan Healthcare Conference
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcement from Stoke Therapeutics or clinical trial registries
Story
Biogen Proposes $442 Million Acquisition of Sage Therapeutics at $7.22 Per Share, Offering 30% Premium as Stock Jumps 35%
Jan 13, 2025, 10:30 AM
Biogen Inc. ($BIIB) has made a nonbinding acquisition proposal to Sage Therapeutics ($SAGE), offering $7.22 per share, which represents a 30% premium over Sage's recent trading price. The total value of the proposed acquisition amounts to approximately $442 million. Following the announcement, Sage Therapeutics' stock surged by 35%, reflecting investor optimism regarding the potential deal. Biogen's CEO, Chris Viehbacher, indicated that the company is actively seeking opportunities in the biotech sector, stating, 'We will be doing deals.' While he did not confirm specific targets, he was asked about the possibility of acquiring Stoke Therapeutics, which is preparing for Phase 3 trials for its treatment of Dravet syndrome. The ongoing discussions and market reactions are expected to be highlighted during the upcoming JPMorgan Healthcare Conference.
View original story
Similar markets
Positive efficacy, but safety concerns • 25%
Negative efficacy and safety concerns • 25%
Positive efficacy and safety results • 25%
Negative efficacy, but good safety • 25%
Worsening condition • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worse outcomes • 25%
Moderate improvement • 25%
No improvement • 25%
Significant improvement • 25%
Full Approval • 25%
Conditional Approval • 25%
Rejection • 25%
Accelerated Approval • 25%
